WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of ...

For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...

Repligen said today it has acquired TangenX Technology from Novasep Holding for $39 million in a deal that adds to the bioprocessing company’s single-use technology offerings and broadens its ...

Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns, ...